Many efforts are being made in trying to develop novel and more effective ways, including both bcr‐abl‐dependent and independent mechanisms 27, 28, to kill CML LSCs without affecting their normal counterparts. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.